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Context: Serum concentration of soluble interleukin-2 receptor (sIL-2R) has been established as a reliable marker of
T-lymphocyte activation. However, there have been no reports describing the relationship between serum sIL-2R
and painless thyroiditis.
Objective: We report a case of a 76-yr-old female with a significant and temporary increase of sIL-2R concomitant
with painless thyroiditis.
Case illustration: The patient was diagnosed with malignant lymphoma at the age of 73. After 6 cycles of CHOP-R
complete remission was induced and no recurrence was observed up to 3.5 years. At 76 years of age, she exhibited
hyperthyroidism and was diagnosed with painless thyroiditis based upon US examination and 99mTc-Thyroid
scintigraphy. Her AST and ALT were mildly elevated, and her serum level of sIL-2R increased up to 2230 U/mL from
the approximately 540 U/mL, which had been stable for 3 years before.
These abnormal data normalized without requiring any treatment. The time-course of the reduction in sIL-2R did
not correlate with FT4 or FT3, but was very similar to that of AST and ALT.
Conclusion: There was no evidence of relapse of the malignant lymphoma. We conclude that the increase of
sIL-2R was associated with painless thyroiditis. Considering the similar time-course between the reduction of serum
sIL-2R and those of AST and ALT, which are often accompanied by autoimmune processes in painless thyroiditis
during the development of hyperthyroidism, it was suggested that the increase of serum sIL-2R in this case resulted
from activation of an autoimmune process.
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The serum concentration of soluble interleukin-2 receptor
(sIL-2R), which is derived from its specific membrane re-
ceptor on activated T lymphocytes [1], has been established
as a reliable marker of T-lymphocyte activation [2]. In auto-
immune hyperthyroidism, such as Graves’ disease, serum
sIL-2R likely increases as a result of T cell activation [3].
This hypothesis is supported by the further increase of
sIL-2R in patients with refractory Graves’ disease [4].
However, it remains possible that hyperthyroidism alone
also increases serum sIL-2R, even in the absence of
autoimmune activation, based on the increase in sIL-2R* Correspondence: inaba-m@med.osaka-cu.ac.jp
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distribution, and reproduction in any mediumthat occurs with triiodothyronine replacement [5]. How-
ever, to date, there has been no report on the relationship
between serum sIL-2R and painless thyroiditis, which is
known as subacute variant of chronic lymphocytic thyroid-
itis,, which is a clinical syndrome that manifests as transient
thyrotoxicosis followed by transient hypothyroidism with-
out spontaneous pain or tenderness in thyroid gland. On
histopathologic analysis, painless thyroiditis manifests as a
lymphocytic infiltration of the thyroid follicles, resulting in
follicular cell damage [6].
Herein, we report a case of a patient who was in re-
mission from large cell type lymphoma with restor-
ation of sIL-2R levels within normal range, and was
being periodically monitored for any potential relapse
of large cell type lymphoma. She exhibited a significanttral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the same time-course as painless thyroiditis.
Case presentation
In January 2007, a 73-year-old female, developed abdominal
pain with pyrexia and was diagnosed with acute appendi-
citis. Examination by computed tomography to further
assess the appendicitis detected disseminated enlargement
of the retroperitoneal lymph nodes and atrophy of the right
kidney surrounded enlargement of multiple lymph nodes.
Since she was suspected to be suffering from malignant
lymphoma, she was then referred to the Department of
Hematology, Osaka City University Hospital on February
7, 2007 for further examination.
She was diagnosed as having malignant lymphoma
(follicular lymphoma Grade 3a, Stage 2), and was treated
with 6 cycles of CHOP-R, which resulted in complete re-
mission. There was no recurrence for another 3.5 years,
and periodic measurements of serum sIL-2R revealed
that her serum sIL-2R remained within the normal
range; around 500 U/ml. In September 2010, she felt
fatigue and palpitation, and subsequently developed
excessive perspiration. She was identified as developing
hyperthyroidism, as reflected by an increase of serum
free T4 and free T3 above the normal upper limit to
3.2 ng/ml and 15.6 pg/ml respectively, with simultan-
eous suppression of serum TSH to <0.004 mIU/l. Of
great importance was the significant increase of sIL-2R
up to 2230 U/ml, which had been stable for 3 years
around 540 U/ml. Once the potential relapse of malig-
nant lymphoma had been ruled out and treatment for
hyperthyroidism had been initiated, she was admitted
to Osaka City University Hospital.
She was 152.0 cm in height and 51.0 kg in weight,
which did not change appreciable before admission. She
did not lose weight. The pulse rate was 72/min and regular,
due probably to administration of atenolol at the daily dose
of 50 mg, and the blood pressure was 132/68 mmHg with a
body temperature of 36.0°C. She had a diffuse and elastic
goiter, but she had neither spontaneous pain nor tenderness
in the anterior neck area. There was no sign of a palpable
cervical lymphoid node and leg edema was absent. The
laboratory findings on admission are presented in Table 1.
Laboratory tests confirmed primary hyperthyroidism,
as indicated by the increase of serum FT4 and FT3
above the respective normal upper limits, with significant
suppression of TSH to an undetectable level. She exhibited
a positive test for anti-thyroglobulin antibody, but was
negative for anti-TSH receptor antibody or anti-thyroid
peroxidase antibody. In addition to hyperthyroidism, the
abnormal findings detected on admission included a slight
reduction of hemoglobin to 10.8 g/dl, mild liver dysfunction
(AST 34 IU/l, ALT 36 IU/l), and slight renal dysfunction,
likely due to total loss of right renal function as a result ofpararenal lymph node enlargement during the onset of
malignant lymphoma.
WBC, white blood cell; RBC, red blood cell; Hb,
Hemoglobin; PLT, platelet; AST, asparate transaminase;
ALT, alanine transaminase; ALP, alkaline phosphatase; LDH,
lactate dehydrogenase; BUN, blood urea nitogen; eGFR,
estimated glomerular filtration rate; CPK, creatine phos-
phokinase; TC, total cholesterol; TG, Triglycerides; FPG,
fasting plasma glucose; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; sIL-2R, soluble interleukin-
2 receptor; FT4, free thyroxine; FT3, free triiodothyronine;
TSH, thyrotropin; TRAb, TSH receptor antibody; TPOAb,
thyroid peroxidase antibody; TgAb, Thyroglobulin antibody.
Ultrasound examination of the thyroid gland showed
destructive thyroiditis, as reflected by the apparent reduc-
tion and heterogeneity of echogenicity inside the thyroid
gland. Intrathyroidal blood flow measured at the inferior
thyroid artery was 24.3 cm/s, which was not as high as the
mean value of 41.5 ± 26.6 m/sec, observed in untreated
Graves’ disease [7]. 99mTc-Thyroid scintigraphy showed
essentially no uptake of 0.187% within the thyroid gland.
Based on these findings, we diagnosed her etiology of
primary hyperthyroidism as painless thyroiditis, and
then monitored her thyroid function without any medi-
cation. Her serum FT4 and FT3 levels decreased rapidly
over time without treatment, whereas her serum sIL-2R
exhibited a sustained increase until the 16th Hospital
day and started to decrease approximately 7 days later.
(Figure 1) Therefore, the reduction of thyroid function
was apparently followed by the reduction of serum sIL-2R.
Of interest, the time-courses of the reductions in AST
and ALT during admission were similar to that of serum
sIL-2R (Figure 2). After the reduction of sIL-2R to around
500 U/ml, it was maintained at a stable range. She was
discharged from our hospital after 21 Hospital days.
When her serum TSH increased above the detectable
lower limit to 0.013 mIu/l 35 days after admission, thyroid
hormone replacement therapy was initiated at a daily dose
of 50 μg L-thyroxine, and this dose was adjusted upward
to 125 μg/day.
The hematologist investigated the possible recurrence
of large cell type lymphoma, which had been in remission
for 3 years before. However, based on her normal findings
on chest and abdominal X-ray CT, with no remarkable
change of LDH, an indicator of lymphoma activity,
the hematologist ruled out the relapse of malignant
lymphoma, which was further supported by the lack of
new manifestation suggesting its recurrence for another
2 years until now.
Discussion
Herein, we report a case in which a significant and tem-
porary increase of serum sIL-2R was detected during an
episode of painless thyroiditis simultaneously with the
Table 1 Laboratory data on admission
Hematology tests eGFR (90<) 41 ml/min/1.7 m2
WBC (4300–8000) 4700 /μl CPK (30–140) 46 IU/l
Neut (49.5–71.0) 56.1% Na (137–146) 136 mEq/l
Mono (2.3–7.7) 10.0% K (3.8-5.1) 4.1 mEq/l
Eos (0.2–6.8) 2.8% Cl (98–108) 105 mEq/l
Baso (0.0–1.8) 0.4% Ca (7.0-10.0) 8.7 mg/dl
Lymph (26.6–46.6) 30.7% P (2.9-4.3) 3.7 mg/dl
RBC (395–465) 349 × 104/μl TC (130–220) 153 mg/dl
Hb (11.3–14.9) 10.8 g/dl TG (50–150) 60 mg/dl
Hematocrit (36–47) 32.2% FPG (70–109) 86 mg/dl
PLT (18.0–34.0) 19.2 × 104 /μl CRP (0–0.4) 0.01 mg/dl
ESR 1 h (2–15) 5 mm
Biochemistry tests sIL-2R (124–466) 2230 U/ml
Total protein (6.5–8.5) 5.8 mg/dl
Albumin (3.5–5.0) 3.9 g/dl Thyroid-related tests
AST (13–33) 34 IU/l FT4 (0.9-1.7) 3.2 ng/dl
ALT (6–27) 36 IU/l FT3 (2.3-4.0) 15.6 pg/ml
ALP (115–359) 189 IU/l TSH (0.5-5.0) <0.004 mIU/l
LDH (119–229) 195 IU/l TRAb (<1.0) <1.0 IU/l
BUN (7–18) 25 mg/dl TPOAb (<0.3) <0.3 IU/ml
Creatinine (0.4–0.9) 1.0 mg/d TgAb (<0.3) 3.9 U/ml
Underlined data is abnormal value.
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supported by the periodic measurement of serum sIL-
2R during ongoing follow-up for the possible relapse of
her malignant lymphoma. This case showed apparent
reduction of serum FT3 and FT4 by the 3rd Hospital
day, although her serum sIL-2R remained at a sustained









Figure 1 Time course of the SIL-2R, FT3 and FT4 levels during admiss
persisted at a high level until the 16th Hospital day and began to decline 1decline 13 days later, after the reduction of serum FT4
and FT3 (Figure 1).
The reason for the increased sIL-2R in hyperthyroidism
is mainly explained by two mechanisms. Hyperthyroidism
alone could increase sIL-2R [5,8,9], in addition to the
hyper-immune state with T cell auto-activation, which
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Figure 2 Time course of SIL-2R, FT3 and FT4 levels during admission. The reduction of sIL-2R was similar to that of the liver enzymes, AST
and ALT.
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positive manner with serum FT3 in non-autoimmune thy-
roiditis, as well as in autoimmune thyroiditis [5]. Further-
more, serum sIL-2R levels have been shown to be higher in
the latter group than in the former; indicating the increase
of sIL-2R as a result of increased autoimmunity, in addition
to hyperthyroidism [5].
Since the increase of sIL-2R persisted, despite the appar-
ent reduction of serum FT4 and FT3 (Figure 1 above), it
was suggested that hyperthyroidism alone could not be
responsible for the increased sIL-2R in this patient. Further
support of this hypothesis is that serum sIL-2R remained
unchanged, around 800 U/ml, even after the reduction of
serum FT4 and F3 below the normal lower limit, with a
significant increase in serum TSH up to 17 mIu/l, although
the hematologist had ruled out the possibility of recurrence
of malignant lymphoma.
Another important mechanism that has been proposed
to increase serum sIL-2R in hyperthyroidism is activation
of the autoimmune process, since serum sIL-2R has been
established as a reliable marker of T-lymphocyte activation
[1]. In fact, it has previously been reported that hyperthyroid
patients with refractory Graves’ disease exhibited higher
levels of serum sIL-2R than would be predicted from
their hyperthyroid state [10]. Furthermore, it has also been
reported that patients with subacute thyroiditis showed
increased sIL-2R; although to date, there is no available
data regarding the association of painless thyroiditis
with increased sIL-2R.
Of great interest, the time course of the reduction in
sIL-2R was similar to that of the liver enzymes, AST and
ALT, during the episode of painless thyroiditis (Figure 2).
It was previously reported that thyroid-liver interaction
in autoimmune thyroid disease is partly explained by the
association of intrinsic liver disease with intrinsic thyroiddisease through autoimmune mechanism(s) [11-13]. Since
the reductions of AST and ALT were delayed by 13 days,
compared with that of serum FT3 and FT4, the increase
of AST and ALT could have occurred by an autoimmune
mechanism, in addition to the hepatotoxic effect of excess
thyroid hormone. Considering the similar time-course
of the reduction of serum sIL-2R with those of AST and
ALT during the episode of hyperthyroidism, which is
often accompanied by the autoimmune process in pain-
less thyroiditis [12,13], it was suggested that the increase
of serum sIL-2R in this case resulted from activation of
the autoimmune process during this episode. However,
since it is reported that the normalization of hypermeta-
bolic state might be delayed for certain period even after
complete normalization of serum FT4 and FT3 within
their respective normal range, it could not be completely
negated that the increase of sIL-2R might be explained by
hyperthyroidism itself.
In conclusion, herein we report the first case of painless
thyroiditis with a significant and temporary increase of
serum sIL-2R.
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